Business Standard

Nod for Covid vaccine in the next few days: Serum Institute's Poonawalla

SII has stockpiled 40-50 mn doses and is adding more every week. Most of these will come to India, as exporting would require fulfilling WHO's pre-qualification procedures

Adar Poonawalla, CEO, Serum Institute
Premium

“Once we get regulatory approvals in a few days, it will depend upon the government to decide how much they can take and how fast,” Poonwalla said.

Ruchika Chitravanshi New Delhi
Serum Institute of India (SII), the world’s largest vaccine maker by volume, is expecting emergency use authorisation for its Covid antidote in a few days, Adar Poonawalla, chief executive officer (CEO), told reporters on Monday.

Poonawalla said Covishield, the vaccine of Oxford-Astra Zeneca, with which SII has an alliance, was likely to get emergency use approval in the UK in a few days and could also secure the regulator’s nod simultaneously in India.

“We will get some good news in this new year ... All the data has been submitted and we must respect the process as regulators are evaluating the data.” 

Pune-based

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in